专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US07317370B2 Ignition coil 失效
标题翻译：点火线圈
公开(公告)号：US07317370B2
公开(公告)日：2008-01-08
申请号：US11707950
申请日：2007-02-20
申请人： Kiyotoshi Nakamoto , Yoshitaka Satoh
发明人： Kiyotoshi Nakamoto , Yoshitaka Satoh
IPC分类号： H01F27/02 , H01F38/12
CPC分类号： H01F38/12 , H01F27/022 , H01F27/04 , H01F27/33 , H01F2038/122
摘要： An ignition coil includes a coil portion that has a primary coil, a secondary coil, and an outer core. The outer core is arranged on a radially outer side of both the primary coil and the secondary coil. A fitting member, which is in a substantially cylindrical shape, has an inner periphery via which the fitting member is fitted to the outer core. A connector case has a fit hole via which the connector case is fitted to an outer periphery of the fitting member. The connector case connects with an axial end of the coil portion via the fitting member. The fitting member includes an embedded member that is at least partially embedded in the fitting member. The embedded member is formed of a material that is different in Young's modulus from a material constructing the fitting member.
摘要翻译：点火线圈包括具有初级线圈，次级线圈和外芯的线圈部分。外芯布置在初级线圈和次级线圈的径向外侧。大致圆筒状的嵌合部件具有内周面，嵌合部件经由该内周嵌合于外芯。连接器壳体具有配合孔，连接器壳体通过该配合孔装配到配件的外周。连接器壳体经由配合构件与线圈部分的轴向端部连接。装配构件包括至少部分地嵌入在装配构件中的嵌入构件。嵌入构件由与构成配合构件的材料的杨氏模量不同的材料形成。

12. 发明授权

US07220771B2 Methods of using indazole derivatives as JNK inhibitors 失效
标题翻译：使用吲唑衍生物作为JNK抑制剂的方法
公开(公告)号：US07220771B2
公开(公告)日：2007-05-22
申请号：US10673121
申请日：2003-09-26
申请人： Shripad S. Bhagwat , Yoshitaka Satoh , Steven T. Sakata , Chris A. Buhr , Ronald Albers , John Sapienza , Veronique Plantevin , Qi Chao , Kiran Sahasrabudhe , Rachel Ferri
发明人： Shripad S. Bhagwat , Yoshitaka Satoh , Steven T. Sakata , Chris A. Buhr , Ronald Albers , John Sapienza , Veronique Plantevin , Qi Chao , Kiran Sahasrabudhe , Rachel Ferri
IPC分类号： A61K31/416 , A61K31/41
CPC分类号： C07D403/12 , C07D231/56 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/14 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/12
摘要： Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.
摘要翻译：公开了具有活性作为JNK的选择性抑制剂的化合物。本发明的化合物是具有以下结构的吲唑衍生物：其中R 1，R 2和A如本文所定义。这些化合物可用于治疗对JNK抑制作用有响应的广泛范围的病症。因此，还公开了治疗这些病症的方法，以及含有一种或多种上述化合物的化合物的药物组合物。

13. 发明申请

US20070060598A1 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith 有权
标题翻译：卤代芳基取代的氨基嘌呤，其组合物及其处理方法
公开(公告)号：US20070060598A1
公开(公告)日：2007-03-15
申请号：US11411413
申请日：2006-04-26
申请人： Ronald Albers , Leticia Ayala , Steven Clareen , Maria Delgado Mederos , Robert Hilgraf , Sayee Hegde , Kevin Hughes , Adam Kois , Veronique Plantevin-Krenitsky , Meg McCarrick , Lisa Nadolny , Moorthy Palanki , Kiran Sahasrabudhe , John Sapienza , Yoshitaka Satoh , Marianne Sloss , Elise Sudbeck , Jonathan Wright
发明人： Ronald Albers , Leticia Ayala , Steven Clareen , Maria Delgado Mederos , Robert Hilgraf , Sayee Hegde , Kevin Hughes , Adam Kois , Veronique Plantevin-Krenitsky , Meg McCarrick , Lisa Nadolny , Moorthy Palanki , Kiran Sahasrabudhe , John Sapienza , Yoshitaka Satoh , Marianne Sloss , Elise Sudbeck , Jonathan Wright
IPC分类号： A61K31/52 , C07D473/14
CPC分类号： A61K31/52 , C07D473/32
摘要： Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.
摘要翻译：本文提供具有以下结构的氨基嘌呤化合物：其中R 1，R 2和R 3如本文所定义，包含有效量的组合物的氨基嘌呤化合物和治疗或预防癌症，心血管疾病，肾脏疾病，自身免疫病症，炎性病症，黄斑变性，缺血再灌注损伤，疼痛和相关综合征，疾病相关性消耗，石棉相关的方法条件，肺动脉高压或通过抑制JNK途径可治疗或可预防的病症，包括向有需要的患者施用有效量的氨基嘌呤化合物。

14. 发明授权

US07122544B2 Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto 有权
标题翻译：苯胺嘧啶衍生物作为IKK抑制剂及其组合物和方法
公开(公告)号：US07122544B2
公开(公告)日：2006-10-17
申请号：US10004642
申请日：2001-12-04
申请人： Adam Kois , Karen J. MacFarlane , Yoshitaka Satoh , Shripad S. Bhagwat , Jason S. Parnes , Moorthy S. S. Palanki , Paul E. Erdman
发明人： Adam Kois , Karen J. MacFarlane , Yoshitaka Satoh , Shripad S. Bhagwat , Jason S. Parnes , Moorthy S. S. Palanki , Paul E. Erdman
IPC分类号： A61K31/506 , C07D403/04
CPC分类号： C07D239/42 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12
摘要： Compounds having activity as inhibitors of IKK are disclosed, particularly IKK-2. The compounds of this invention are anilinopyrimidine derivatives having the following structure: wherein R1 and R6 are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.
摘要翻译：公开了具有IKK抑制剂活性的化合物，特别是IKK-2。本发明的化合物是具有以下结构的苯胺基嘧啶衍生物：其中R 1和R 6如本文所定义。这些化合物可用于治疗对IKK抑制有反应的广泛范围的病症。因此，还公开了治疗这些病症的方法，以及含有一种或多种上述化合物的化合物的药物组合物。

15. 发明申请

US20050009876A1 Indazole compounds, compositions thereof and methods of treatment therewith 审中-公开
标题翻译：吲唑化合物，其组合物及其处理方法
公开(公告)号：US20050009876A1
公开(公告)日：2005-01-13
申请号：US10718185
申请日：2003-11-19
申请人： Shripad Bhagwat , Yoshitaka Satoh , Steven Sakata , Chris Buhr , Ronald Albers , John Sapienza , Veronique Plantevin , Qi Chao , Kiran Sahasrabudhe , Rachel Ferri , Rama Narla
发明人： Shripad Bhagwat , Yoshitaka Satoh , Steven Sakata , Chris Buhr , Ronald Albers , John Sapienza , Veronique Plantevin , Qi Chao , Kiran Sahasrabudhe , Rachel Ferri , Rama Narla
IPC分类号： A61K31/416 , C07D231/56 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/12 , A61K31/4439 , A61K31/4162 , C07
CPC分类号： A61K31/454 , A61K31/416 , C07D231/56 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/12
摘要： This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.
摘要翻译：本发明一般涉及吲唑化合物用于治疗或预防与蛋白激酶相关的疾病，包括酪氨酸激酶，例如增殖性疾病，炎性疾病，异常血管发生及其相关疾病，动脉粥样硬化，黄斑变性，糖尿病，肥胖症，疼痛和别的。所述方法包括向有需要的患者施用有效量的抑制，调节或调节酪氨酸激酶信号转导的吲唑化合物。本文给出了新的吲唑化合物或其药学上可接受的盐。

16. 发明授权

US5520847A Low-velocity electron excited phosphor 失效
标题翻译：低速电子激发荧光粉
公开(公告)号：US5520847A
公开(公告)日：1996-05-28
申请号：US247994
申请日：1994-05-24
申请人： Yoshitaka Satoh , Hitoshi Toki , Fumiaki Kataoka , Shigeo Itoh
发明人： Yoshitaka Satoh , Hitoshi Toki , Fumiaki Kataoka , Shigeo Itoh
IPC分类号： C09K11/64 , H01J31/15 , C09K11/57 , C09K11/54
CPC分类号： C09K11/642
摘要： A low-velocity electron excited phosphor having a composition represented by a general formula ZnO.multidot.(Al.sub.x, Ga.sub.l-x).sub.2 O.sub.3 :Mn, wherein X=0.001 to 0.3 mol. A content of Al in the phosphor is set be to within a range between 0.001 mol and 0.3 mol. The range permits a variation in luminance of the phosphor to be within .+-.30% and initial luminance of the phosphor to be significantly increased, resulting in the phosphor being suitable for use for a fluorescent display device.
摘要翻译：具有由通式ZnO x（Al x，Gal-x）2 O 3：Mn表示的组成的低速电子激发的荧光体，其中X = 0.001〜0.3mol。荧光体中的Al含量设定在0.001mol〜0.3mol的范围内。该范围允许荧光体的亮度变化在±30％以内，并且荧光体的初始亮度显着增加，导致荧光体适合用于荧光显示装置。

17. 发明申请

US20100093698A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH 有权
标题翻译：氨基三唑基吡啶类，其组合物及其处理方法
公开(公告)号：US20100093698A1
公开(公告)日：2010-04-15
申请号：US12555018
申请日：2009-09-08
申请人： Sogole Bahmanyar , R.J. Bates , Kate Blease , Andrew Antony Calabrese , Thomas Oran Daniel , Mercedes Delgado , Jan Elsner , Paul Erdman , Bruce Fahr , Gregory Ferguson , Branden Lee , Lisa Nadolny , Garrick Packard , Patrick Papa , Veronique Plantevin-Krenitsky , Jennifer Riggs , Patricia Rohane , Sabita Sankar , John Sapienza , Yoshitaka Satoh , Victor Sloan , Randall Stevens , Lida Tehrani , Jayashree Tikhe , Eduardo Torres , Andrew Wallace , Brandon Wade Whitefield , Jingjing Zhao
发明人： Sogole Bahmanyar , R.J. Bates , Kate Blease , Andrew Antony Calabrese , Thomas Oran Daniel , Mercedes Delgado , Jan Elsner , Paul Erdman , Bruce Fahr , Gregory Ferguson , Branden Lee , Lisa Nadolny , Garrick Packard , Patrick Papa , Veronique Plantevin-Krenitsky , Jennifer Riggs , Patricia Rohane , Sabita Sankar , John Sapienza , Yoshitaka Satoh , Victor Sloan , Randall Stevens , Lida Tehrani , Jayashree Tikhe , Eduardo Torres , Andrew Wallace , Brandon Wade Whitefield , Jingjing Zhao
IPC分类号： A61K31/437 , C07D471/02 , A61K31/5377 , A61K31/497 , A61K31/55
CPC分类号： C07D471/04 , C07D519/00
摘要： Provided herein are Heteroaryl Compounds of formula (I): wherein R1 and R2 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing inflammatory conditions or cancer, and conditions treatable or preventable by inhibition of a kinase or a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a subject in need thereof.
摘要翻译：本文提供了式（I）的杂芳基化合物：其中R 1和R 2如本文所定义，包含有效量的杂芳基化合物的组合物和用于治疗或预防炎性病症或癌症的方法，以及可通过抑制激酶治疗或预防的病症或激酶途径，其包括向有需要的受试者施用有效量的杂芳基化合物。

18. 发明授权

US07521446B2 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith 有权
标题翻译：卤代芳基取代的氨基嘌呤，其组合物及其处理方法
公开(公告)号：US07521446B2
公开(公告)日：2009-04-21
申请号：US11411413
申请日：2006-04-26
申请人： Ronald J. Albers , Leticia Ayala , Steven S. Clareen , Maria Mercedes Delgado Mederos , Robert Hilgraf , Kevin Hughes , Adam Kois , Veronique Plantevin-Krenitsky , Meg McCarrick , Lisa Nadolny , Moorthy S. S. Palanki , Kiran Sahasrabudhe , Yoshitaka Satoh , Marianne K. Sloss , Elise Sudbeck , Jonathan Wright
发明人： Ronald J. Albers , Leticia Ayala , Steven S. Clareen , Maria Mercedes Delgado Mederos , Robert Hilgraf , Kevin Hughes , Adam Kois , Veronique Plantevin-Krenitsky , Meg McCarrick , Lisa Nadolny , Moorthy S. S. Palanki , Kiran Sahasrabudhe , Yoshitaka Satoh , Marianne K. Sloss , Elise Sudbeck , Jonathan Wright
IPC分类号： C07D473/32 , A61K31/52 , A61P3/10 , A61P11/00 , C07D239/50 , C07D239/48
CPC分类号： A61K31/52 , C07D473/32
摘要： Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.
摘要翻译：本文提供具有以下结构的氨基嘌呤化合物：其中R1，R2和R3如本文所定义，包含有效量的氨基嘌呤化合物的组合物和治疗或预防癌症，心血管疾病，肾脏疾病，自身免疫病症，炎性病症，黄斑变性，缺血再灌注损伤，疼痛和相关综合征，疾病相关性消耗，石棉相关病症，肺动脉高压或通过抑制JNK途径可治疗或可预防的病症包括给予有效量的氨基嘌呤与需要的患者复合。

19. 发明申请

US20070210888A1 Ignition coil 失效
标题翻译：点火线圈
公开(公告)号：US20070210888A1
公开(公告)日：2007-09-13
申请号：US11707950
申请日：2007-02-20
申请人： Kiyotoshi Nakamoto , Yoshitaka Satoh
发明人： Kiyotoshi Nakamoto , Yoshitaka Satoh
IPC分类号： H01F27/02
CPC分类号： H01F38/12 , H01F27/022 , H01F27/04 , H01F27/33 , H01F2038/122
摘要： An ignition coil includes a coil portion that has a primary coil, a secondary coil, and an outer core. The outer core is arranged on a radially outer side of both the primary coil and the secondary coil. A fitting member, which is in a substantially cylindrical shape, has an inner periphery via which the fitting member is fitted to the outer core. A connector case has a fit hole via which the connector case is fitted to an outer periphery of the fitting member. The connector case connects with an axial end of the coil portion via the fitting member. The fitting member includes an embedded member that is at least partially embedded in the fitting member. The embedded member is formed of a material that is different in Young's modulus from a material constructing the fitting member.
摘要翻译：点火线圈包括具有初级线圈，次级线圈和外芯的线圈部分。外芯布置在初级线圈和次级线圈的径向外侧。大致圆筒状的嵌合部件具有内周面，嵌合部件经由该内周嵌合于外芯。连接器壳体具有配合孔，连接器壳体通过该配合孔装配到配件的外周。连接器壳体经由配合构件与线圈部分的轴向端部连接。装配构件包括至少部分地嵌入在装配构件中的嵌入构件。嵌入构件由与构成配合构件的材料的杨氏模量不同的材料形成。

20. 发明授权

US07129242B2 Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto 失效
标题翻译：苯丙嘧啶衍生物作为JNK途径抑制剂及其组合物和方法
公开(公告)号：US07129242B2
公开(公告)日：2006-10-31
申请号：US10004645
申请日：2001-12-04
申请人： Yoshitaka Satoh , Shripad S. Bhagwat
发明人： Yoshitaka Satoh , Shripad S. Bhagwat
IPC分类号： A61K31/50 , A61K31/497
CPC分类号： C07D239/42 , A61K31/496 , A61K31/505 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D487/08 , C07D491/10 , A61K2300/00
摘要： Compounds having activity as inhibitors of the JNK pathway are disclosed. The compounds of this invention are anilinopyrimidine derivatives having the following structure: wherein R1 through R6 are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.
摘要翻译：公开了具有JNK途径抑制剂活性的化合物。本发明的化合物是具有以下结构的苯胺基嘧啶衍生物：其中R 1至R 6如本文所定义。这些化合物可用于治疗对抑制JNK通路有反应的广泛的条件。因此，还公开了治疗这些病症的方法，以及含有一种或多种上述化合物的化合物的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式